Core Viewpoint - The article discusses the impact of depression on individuals, particularly in impoverished communities, highlighting the stigma and misunderstanding surrounding mental health issues, and the importance of recognizing and treating depression as a legitimate medical condition rather than a sign of laziness or moral failing [15][21][27]. Group 1: Patient Case Study - The patient, Chen Degui, comes from a poor rural background, facing significant barriers to accessing medical care, which took him four days to reach a hospital in Beijing [2][14]. - Degui's family has a history of mental health issues, with multiple family members exhibiting symptoms of depression, leading to tragic outcomes such as suicide [6][9][13]. - The narrative illustrates how poverty exacerbates mental health conditions, with Degui's experiences reflecting a broader issue of how societal perceptions can hinder proper diagnosis and treatment [15][16][21]. Group 2: Understanding Depression - The article emphasizes that depression is often mischaracterized as a "rich person's disease," while in reality, impoverished individuals are at a higher risk, with studies indicating that the likelihood of depression is twice as high among the poor compared to the general population [15][21]. - It discusses the phenomenon of somatization, where emotional distress manifests as physical symptoms, complicating the diagnosis of depression in low-income patients [16][19]. - The genetic predisposition to depression is highlighted, with research indicating a high heritability rate, suggesting that some families may be more susceptible to these conditions due to genetic factors [21][22]. Group 3: Treatment and Recovery - The article describes the treatment approach for Degui, which includes prescribing Amitriptyline, a cost-effective antidepressant that can alleviate both emotional and physical symptoms associated with depression [20][21]. - It emphasizes the importance of ongoing treatment and the need for patients to adhere to medication regimens to prevent relapse, as well as the necessity of changing societal perceptions about mental health [26][27]. - The narrative concludes with a hopeful note on Degui's recovery, illustrating the transformative power of proper treatment and the potential for individuals to regain a sense of purpose and joy in life [24][26].

Investment Rating - The report does not explicitly state an investment rating for the industry [1]. Core Insights - Adult cancer pain management is a systematic project aimed at achieving comprehensive pain control through standardized assessment, individualized treatment, and multidisciplinary collaboration [4]. - Cancer pain is a prevalent symptom among cancer patients, with a high incidence rate of 44.5%, and nearly one-third of patients suffer from moderate to severe pain [11]. - The adult cancer pain treatment market in China is expected to grow from 3.76 billion CNY in 2020 to 6.36 billion CNY by 2029, with a compound annual growth rate (CAGR) of 6.8% from 2020 to 2024 and 5.3% from 2025 to 2029 [20]. Summary by Sections Cancer Pain Management - Cancer pain management involves a comprehensive approach that includes pain screening, assessment, and management tailored to the patient's overall treatment goals [3][4]. - The management process is based on standardized screening and dynamic assessment, following principles of regularity, quantification, comprehensiveness, and dynamism [4]. Epidemiological Characteristics - Cancer pain has a high prevalence among patients, particularly in advanced stages, where over 80% experience pain [11]. - The main causes of cancer pain are tumor progression (over 90%) and treatment-related pain (approximately 20%) [11]. - Pain types include nociceptive pain (around 60%), neuropathic pain (19%), and mixed pain (20%) [11]. Treatment Medications - Common medications for cancer pain include weak opioids (e.g., codeine, tramadol), strong opioids (e.g., morphine, fentanyl), non-steroidal anti-inflammatory drugs (NSAIDs), and acetaminophen [15][16]. - There is a shift towards the development of non-opioid medications to provide safer and sustainable pain management options [16]. Market Outlook - The adult cancer pain treatment market is projected to expand significantly due to increasing clinical needs and the introduction of innovative non-opioid drugs [19][20]. - The treatment rate for cancer pain is expected to rise from approximately 70% to 90% by 2029, indicating a growing population receiving standardized treatment [20]. Innovation Trends - Treatment strategies are transitioning from reliance on opioids to a multimodal approach that includes NSAIDs and adjuvant analgesics [26]. - The focus on non-opioid innovative drugs is becoming a breakthrough direction in drug development [26]. - There is an emphasis on personalized medication management and the establishment of a comprehensive management network through medical alliances [26][27].